Neoadjuvant Radiotherapy and Surgery for High-Risk Localized Ewing Sarcoma
Trial statusNot yet recruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age12+
SponsorPeking University People's Hospital
About this trial
This is a single-center, single-arm, prospective observational study to evaluate the long-term local control rate, safety, and efficacy of preoperative neoadjuvant radiotherapy (36-45 Gy) followed by sequential radical surgery and postoperative chemotherapy in patients with high-risk, resectable localized Ewing sarcoma.
Eligibility criteria
Qualifiers
The subject or their legal representative signs the written informed consent prior to enrollment.
Age <= 55 years old.
Histologically confirmed Ewing sarcoma, with FET family (including EWSR1 or FUS) gene rearrangement confirmed by FISH or NGS. Clear FET-non ETS fusion cases are excluded.
Deemed difficult to achieve a satisfactory surgical margin by 2 or more senior musculoskeletal oncologists.
Disqualifiers
No opportunity for surgical resection after neoadjuvant chemotherapy.
Extensive metastasis with no indication for local surgical resection.
Uncontrolled concurrent medical conditions.
Prior radiotherapy to the surgical site during front-line treatment.
Trial design
Treatments tested in this trial
- Not listed
Trial groups
No trial groups listed
Sponsors and collaborators
Source ClinicalTrials.gov